Fc gamma RIIIA / CD16a
Fc gamma RIIIA / CD16a 詳細
| 英語名 | Low affinity immunoglobulin gamma Fc region receptor III-A | 市販薬剤の数 | 0 |
| 治験薬の数 | 14 | ターゲットの別称 | IGFR3，FCG3，Fc Fragment Of IgG， Low Affinity IIIa， Receptor For (CD16)，Fc Fragment Of IgG， Low Affinity III， Receptor For (CD16)，Immunoglobulin G Fc Receptor III，Fc-Gamma Receptor III-2 (CD 16)，Neutrophil-Specific Antigen NA，Fc-Gamma Receptor IIIb (CD16)，Fc Gamma Receptor III-A，Low Affinity Immunoglobulin Gamma Receptor III-A Fc Fragment，IgG Fc receptor III-2，Low affinity immunoglobulin gamma Fc region receptor III-A，FCGR3，CD16A，Fc-gamma RIII-alpha，FCGR3A，Fc Fragment Of IgG Receptor IIIa，Fc Fragment Of IgG， Low Affinity IIIa， Receptor (CD16a)，CD16a Antigen，Fc Gamma Receptor IIIa，Fc-Gamma RIIIa，Fc-Gamma RIII，FcgammaRIIIA，FCGRIII，FcRIIIa，FCR-10，FCRIII，IMD20，CD16 |
| 研究＆開発段階 | Phase 2 Clinical | ||
| 英語名 | Low affinity immunoglobulin gamma Fc region receptor III-A |
| ターゲットの別称 | IGFR3，FCG3，Fc Fragment Of IgG， Low Affinity IIIa， Receptor For (CD16)，Fc Fragment Of IgG， Low Affinity III， Receptor For (CD16)，Immunoglobulin G Fc Receptor III，Fc-Gamma Receptor III-2 (CD 16)，Neutrophil-Specific Antigen NA，Fc-Gamma Receptor IIIb (CD16)，Fc Gamma Receptor III-A，Low Affinity Immunoglobulin Gamma Receptor III-A Fc Fragment，IgG Fc receptor III-2，Low affinity immunoglobulin gamma Fc region receptor III-A，FCGR3，CD16A，Fc-gamma RIII-alpha，FCGR3A，Fc Fragment Of IgG Receptor IIIa，Fc Fragment Of IgG， Low Affinity IIIa， Receptor (CD16a)，CD16a Antigen，Fc Gamma Receptor IIIa，Fc-Gamma RIIIa，Fc-Gamma RIII，FcgammaRIIIA，FCGRIII，FcRIIIa，FCR-10，FCRIII，IMD20，CD16 |
| 市販薬剤の数 | 0 |
| 治験薬の数 | 14 |
| 研究＆開発段階 | Phase 2 Clinical |
Fc gamma RIIIA / CD16a 製品リスト
- 属性
Protein (7)Cell (5)Kits (2)
- 製品ライブラリ
オンライン (14)
- 種
Human (14)
- タグ
His Tag (3)His Tag & Avi Tag (2)His Tag & SUMO Tag (1)His Tag & HSA Tag (1)- (7)
- マーカー
Unconjugated (5)Biotin-labeled (2)- (7)
総数量14
- 1
- 2
Fc gamma RIIIA / CD16aバックグランド
CD16 is a low affinity Fc receptor, and has been identified as Fc receptors FcγRIIIa (CD16a) and FcγRIIIb (CD16b). These receptors bind to the Fc portion of IgG antibodies. CD16 encoded by two different highly homologous genes in a cell type-specific manner.CD16 is found on the surface of natural killer cells, neutrophil polymorphonuclear leukocytes, monocytes and macrophages.
CD16a antigen is also known as Low affinity immunoglobulin gamma Fc region receptor III-A, Fc-gamma RIII-alpha. CD16b is a low-affinity, GPI-linked receptor expressed by neutrophils and eosinophils, whereas CD16a is an intermediate affinity polypeptide-anchored transmembrane glycoprotein expressed natural killer cells, macrophages, subpopulation of T-cells, immature thymocytes and placentaltrophoblasts.CD16a is involved in phagocytosis, secretion of enzymes and inflammatory mediators, antibodydependent cytotoxicity and clearance of immune complexes. Aberrant expression or mutations of CD16a is implicated in susceptibility to recurrent viral infections, systemic lupus erythematosus, and alloimmune neonatal neutropenia.
Fc gamma RIIIA / CD16a分子の別称
FCGR3A,CD16A,FCG3,FCGR3,IGFR3
抗体購入プラットフォーム
| プロジェクト | ステージ | タイプ | 由来 | 疾患領域 | 適応症 |
|---|---|---|---|---|---|
| CD16a VHH - 01 | PCC | Monoclonal | Nanobody | Solid Tumor | Solid tumor,Hematoma |
治験薬に関する情報
| 英語名 | 研究コード | 研究開発ステージ | 会社 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|
| Acimtamig | AFM-13 | Phase 2 Clinical | The University Of Texas MD Anderson Cancer Center | Hodgkin Disease; Lymphoma, B-Cell; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Peripheral; Mycosis Fungoides | 詳細 |
| IPH-6501 | IPH-6501; IPH-65 | Phase 2 Clinical | Innate Pharma SA | Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Neoplasms | 詳細 |
| FT-538 | FT-538 | Phase 2 Clinical | Fate Therapeutics Inc | Coronavirus Disease 2019 (COVID-19); Fallopian Tube Neoplasms; HIV Infections; Leukemia, Monocytic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms; Respiratory Distress Syndrome, Adult; Solid tumours | 詳細 |
| GMA-161 | GMA-161 | Phase 1 Clinical | Macrogenics Inc, Sanofi | Purpura, Thrombocytopenic, Idiopathic | 詳細 |
| GTB-5550 | GTB-5550; B7H3 TriKE™; cam1615B7H3; GTB-5550 TriKE™ | Phase 1 Clinical | University Of Minnesota | Solid tumours | 詳細 |
| FT-576 | FT-576 | Phase 1 Clinical | Fate Therapeutics Inc, University Of Minnesota | Bone Marrow Neoplasms; Multiple Myeloma | 詳細 |
| AFM-28 | AFM-28 | Phase 1 Clinical | Affimed | Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Neoplasms | 詳細 |
| Donor-derived CD123-CD16 bispecific antibody-modified NK cells therapy(Chinese PLA General Hospital) | Phase 1 Clinical | Pla General Hospital | Leukemia, Myeloid, Acute | 詳細 | |
| GTB-3650 | GTB-3650; GTB-360; OXS-3350; OXS-C3550 | Phase 1 Clinical | Masonic Cancer Center, University Of Minnesota | Bone Marrow Neoplasms; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 詳細 |
| BGB-B3227 | BGB-B3227 | Phase 1 Clinical | BeOne Medicines (Beijing) Co Ltd | Gastrointestinal Neoplasms; Lung Neoplasms; Neoplasm Metastasis; Neoplasms; Solid tumours | 詳細 |
| SM-3321 | SM-3321; SM3321 | Phase 1 Clinical | Zhuhai StarMab BioMed Technology Ltd | Leukemia, Myeloid, Acute; Neoplasms | 詳細 |
| FT-596 | FT-596 | Phase 1 Clinical | Fate Therapeutics Inc | Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin | 詳細 |
| SAR-443579 | SAR-443579; SAR443579; SAR'579; IPH6101; IPH-6101 | Phase 1 Clinical | Sanofi | Blastic Plasmacytoid Dendritic Cell Neoplasm; Hematologic Diseases; Leukemia, B-Cell; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 詳細 |
| FT-516 | FT-516 | Phase 1 Clinical | Fate Therapeutics Inc, University Of Minnesota | Abdominal Neoplasms; Coronavirus Disease 2019 (COVID-19); Fallopian Tube Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, B-Cell; Ovarian Neoplasms; Solid tumours | 詳細 |
レビュー
A***n2025-02-12
0評価Acro's Fc gamma receptor proteins are my top choice for Octet binding assays. They consistently deliver reliable results, crucial for accurate research. Their product quality is outstanding, ensuring reproducible experiments. Acro's technical service is exceptional, with a responsive and knowledgeable support team. Their comprehensive range of well-characterized Fc receptor proteins, high purity, and bioactivity have made them my exclusive supplier. The attention to quality control ensures excellent batch-to-batch consistency.- W***u2024-10-08 0評価We used this biotin labeled protein in the ELISA assay and we have got reproducible and high-quality results. Also I want to mention and there is no degradation or activity changes of this product over more than half year, which made it our experiment easier without bridging assay.
- J***n2023-06-24 3評価We used the biotinylated human Fc gamma RIIIA material from Acro to test the binding of different human antibodies. The material arrived quickly and in time for our experiments. I used the material with the Biacore 8K (SPR) instrument using Series S Biotin CAP chip. We were happy with how the material worked in this assay format. Overall, we were pleased with the quality and would recommend this to other researchers.
詳しく読む
- 詳細
- 製品リスト
- レビュー
- 治験薬に関する情報